UMMS Affiliation

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

Publication Date

2021-04-22

Document Type

Article

Disciplines

Allergy and Immunology | Bacterial Infections and Mycoses | Endocrine System Diseases | Immunology and Infectious Disease | Infectious Disease | Microbiology | Nutritional and Metabolic Diseases

Abstract

Objectives: To study the association of Tissue inhibitors of matrix metalloproteinases (TIMP) levels with tuberculosis-diabetes comorbidity (TB-DM) comorbidity at baseline and in response to anti-TB treatment (ATT).

Methods: We examined the levels of TIMP-1, -2, -3 and -4 in pulmonary tuberculosis alone (TB) or TB-DM at baseline and after ATT.

Results: TIMP-1, -3 and -4 were significantly increased in TB-DM compared to TB at baseline and after ATT. ATT resulted in a significant reduction in TIMP-2 and -3 levels and a significant increase in TIMP-1 in both TB and TB-DM. TIMP-1, -3 and -4 were also significantly increased in TB-DM individuals with bilateral, cavitary disease and also exhibited a positive relationship with bacterial burden in TB-DM and HbA1c in all TB individuals. Within the TB-DM group, those known to be diabetic before incident TB (KDM) exhibited higher levels of TIMP-1, -2, -3 and -4 at baseline and TIMP-2 at post-treatment compared to those newly diagnosed with DM (NDM). KDM individuals on metformin treatment exhibited lower levels of TIMP-1, -2 and -4 at baseline and of TIMP-4 at post-treatment.

Conclusions: TIMP levels were elevated in TB-DM, associated with disease severity and bacterial burden, correlated with HbA1c levels and modulated by duration of DM and metformin treatment.

Keywords

Diabetes mellitus, Mycobacterium tuberculosis, Tissue inhibitors of metalloproteinases

Rights and Permissions

Copyright © 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of Published Version

10.1016/j.jctube.2021.100237

Source

Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Hissar S, Kornfeld H, Babu S. Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity. J Clin Tuberc Other Mycobact Dis. 2021 Apr 22;23:100237. doi: 10.1016/j.jctube.2021.100237. PMID: 33997311; PMCID: PMC8100611. Link to article on publisher's site

Journal/Book/Conference Title

Journal of clinical tuberculosis and other mycobacterial diseases

Related Resources

Link to Article in PubMed

PubMed ID

33997311

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS